Treatment options for lower-risk myelodysplastic syndromes. Where are we now?

por Volpe, Virginia O., Komrokji, Rami S.
Publicado 2021

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update

por Jain, Akriti G., Zhang, Ling, Bennett, John M., Komrokji, Rami
Publicado 2022

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

por Abou Zahr, Abdallah, Saad Aldin, Ehab, Komrokji, Rami S, Zeidan, Amer M
Publicado 2014

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

por Cluzeau, Thomas, Loschi, Michael, Fenaux, Pierre, Komrokji, Rami, Sallman, David A.
Publicado 2021

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned

por Pinilla-Ibarz, Javier, Sweet, Kendra L, Corrales-Yepez, Gabriela M, Komrokji, Rami S
Publicado 2016

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

por Kuykendall, Andrew T., Horvat, Nathan P., Pandey, Garima, Komrokji, Rami, Reuther, Gary W.
Publicado 2020

Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare association

por Zhang, Yumeng, Varnadoe, Christa, Tandon, Ankita, Forsyth, Peter, Komrokji, Rami, Sokol, Lubomir
Publicado 2020

Telomerase-targeted therapies in myeloid malignancies

por Waksal, Julian A., Bruedigam, Claudia, Komrokji, Rami S., Jamieson, Catriona H. M., Mascarenhas, John O.
Publicado 2023

P1045: DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST

por Komrokji, Rami S., Grunwald, Michael, Braunstein, Evan, Hamer-Maansson, J.E., Kalafut, Tricia, Mascarenhas, John
Publicado 2023

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

por Singer, Jack W, Al-Fayoumi, Suliman, Ma, Haiching, Komrokji, Rami S, Mesa, Ruben, Verstovsek, Srdan
Publicado 2016

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis COMFORT-I

por Miller, Carole B., Komrokji, Rami S., Mesa, Ruben A., Sun, William, Montgomery, Michael, Verstovsek, Srdan
Publicado 2017

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)

por Komrokji, Rami S., Hernandez- Donoso, Leyla, Hodzic, Sejla, Owusu, Henry, Nolan, Kevin, Nourry, Claire, Campelo, María Díez
Publicado 2023

U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes

por Komrokji, Rami, Aguirre, Luis E., Al Ali, Najla, Hussaini, Mohamad, Sallman, David, Rollison, Dana, Padron, Eric
Publicado 2022

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)

por Brunner, Andrew M., Gavralidis, Alexander, Ali, Najla Al, Hunter, Anthony, Komrokji, Rami, Zeidan, Amer, Sallman, David A.
Publicado 2022

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy

por Komrokji, Rami, al Ali, Najla, Chan, Onyee, Sweet, Kendra, Kuykendall, Andrew, Lancet, Jeffrey, Padron, Eric, Sallman, David A.
Publicado 2022

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

por Komrokji, Rami S., Singh, Avani M., Ali, Najla Al, Chan, Onyee, Padron, Eric, Sweet, Kendra, Kuykendall, Andrew, Lancet, Jeffrey E., Sallman, David A.
Publicado 2022

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

por Garcia-Manero, Guillermo, Santini, Valeria, Fenaux, Pierre, Suzuki, Takahiro, Sekeres, Mikkael, He, Jun, Barkalifa, Ronit, Vigil, Carlos, Prebet, Thomas, Komrokji, Rami S., Giagounidis, Aristoteles
Publicado 2023

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS

por Sallman, David A, Komrokji, Rami, Cluzeau, Thomas, Vaupel, Christine, Al Ali, Najla H, Lancet, Jeffrey, Hall, Jeff, List, Alan, Padron, Eric, Song, Jinming
Publicado 2017

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

por Komrokji, Rami S., Carraway, Hetty E., Germing, Ulrich, Wermke, Martin, Zeidan, Amer M., Fu, Eric, Rüter, Björn, Burkard, Ute, Osswald, Annika, Foran, James M.
Publicado 2022

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

por Komrokji, Rami S., Aguirre, Luis E., Al Ali, Najla H., Chan, Onyee, Xie, Zhuoer, Kuykendall, Andrew, Sweet, Kendra, Lancet, Jeffrey E., Padron, Eric, Sallman, David A.
Publicado 2023